Scholarlink

<p>Radiotheranostics is revolutionizing nuclear medicine by integrating diagnostic imaging and targeted radionuclide therapy using radiolabeled biomolecules. This paper highlights the current landscape of radiotheranostics in Malaysia, addressing advancements, challenges, and prospects for integrating novel biomolecules, enhancing infrastructure, and expanding access to personalized radiopharmaceutical therapies. Nuclear medicine centers in Malaysia have been operational for nearly sixty years, with approximately 40 facilities available country-wide and radiotheranostics is gaining momentum, particularly in the diagnosis and treatment of neuroendocrine tumors and prostate cancer using peptide receptor radionuclide therapy and prostate-specific membrane antigen-based theranostics. Despite significant progress, challenges such as limited local radionuclide production, uneven distribution of radiotheranostics centers, reliance on imports, and regulatory constraints hinder widespread adoption. The implementation of Malaysia’s National Strategic Plan for Cancer Control Programme (2021–2025) underscores the growing need for sustainable theranostic solutions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Current Status and Advancements in Radiotheranostics and Targeted Radionuclide Therapy in Malaysia

  • 期刊论文

  • 发表日期：

    2025年10月29日

查看全文
  • Muhammad Fakhrurazi Ahmad Fadzil,
  • Zarif Ashhar,
  • Azahari Kasbollah,
  • Zaitulhusna Md Safee,
  • Siti Fazira Edzua Jamaludin,
  • Akram Al-Ibraheem

摘要

Radiotheranostics is revolutionizing nuclear medicine by integrating diagnostic imaging and targeted radionuclide therapy using radiolabeled biomolecules. This paper highlights the current landscape of radiotheranostics in Malaysia, addressing advancements, challenges, and prospects for integrating novel biomolecules, enhancing infrastructure, and expanding access to personalized radiopharmaceutical therapies. Nuclear medicine centers in Malaysia have been operational for nearly sixty years, with approximately 40 facilities available country-wide and radiotheranostics is gaining momentum, particularly in the diagnosis and treatment of neuroendocrine tumors and prostate cancer using peptide receptor radionuclide therapy and prostate-specific membrane antigen-based theranostics. Despite significant progress, challenges such as limited local radionuclide production, uneven distribution of radiotheranostics centers, reliance on imports, and regulatory constraints hinder widespread adoption. The implementation of Malaysia’s National Strategic Plan for Cancer Control Programme (2021–2025) underscores the growing need for sustainable theranostic solutions.